6th RSC-BMCS / DMDG New Perspectives in DMPK
Event
6th RSC / DMDG New Perspectives in DMPK
Date
Monday 17th June 2024
Place
Liverpool Medical Institute, Liverpool, UK
Downloads and Links
Twitter hashtag – #DMPK24
To download the first announcement poster, click here
To download the second announcement poster, click here
Novel small-molecule-based therapeutic approaches represent a key component of the discovery landscape. The emergence of molecular glues, PROTACs, bicyclic peptides, and other novel chemistries often bring with them new challenges for drug discovery scientists; synthetic difficulty, beyond rule-of-five physicochemical properties, and complexity in the link between exposure and response, may complicate ADME characterisation and accurate human dose prediction, particularly for drugs aimed at oral administration.
This meeting will provide a forum for the exchange of ideas between principal members of the DMPK research community on how we can rise to these challenges. Keynote talks from thought leaders will provide wider perspectives on how DMPK can contribute to the delivery of medicines to patients more quickly and efficiently. There will be a balanced mix of oral and poster presentations, and networking opportunities throughout.
Who should attend
Medicinal chemists, drug discovery scientists, pharmacologists, toxicologists, DMPK scientists – from academia, industry, and third sector institutions.
Want to know more?
Call for Abstracts
Poster abstract submissions are now closed!
Bursaries
The RSC-BMCS and the DMDG are offering a bursary each, to attend the meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions or non-profit institutions. Bursary applications are also invited from RSC or EFMC members who are of working age, but currently unemployed, and from those who may have difficulty in funding themselves or whose organisations may have difficulty in funding their attendance.
Bursary submissions are now closed!
Programme
| 08:30 | Registration |
| 09:15 | Introduction Andrew Stachulski, University of Liverpool |
| Chair: Xiaoli Meng, Liverpool University | |
| 09:30 | Keynote: Why are intractable targets difficult to drug with small molecules? How can we improve druggability? Kevin Beaumont, AstraZeneca |
| 10:15 | Flash Presentations F01 In vitro-in vivo extrapolation of clearance - a current challenge for proteolysis-targeting chimeras Christine Maurer, Merck Healthcare KgaA F02 Optimization of the Assay Conditions to Increase Recovery in Caco-2 Permeability Assay for PROTACs Yuliia Holota, Enamine F03 Evaluations of Antibiotics Teixobactins against Multidrug-Resistant Bacteria and Biofilms Tsz Ying To, University of Liverpool F04 Using AI/ML-Methodology for the Prediction of Oral Bioavailability of Drugs and Systemic Exposure of Drug Metabolites in Humans Urban Fagerholm, Prosilico F05 Novel plasma protein binding ‘membrane-free’ assay delivers fraction unbound values for beyond rule of 5 compounds Zichen He, AstraZeneca |
| 10:45 | Refreshment break and Poster viewing |
| 11:15 | Keynote: A medicinal chemistry approach to access the diverse teixobactins: a new class of antibiotics Ishwar Singh, University of Liverpool |
| 12:00 | ADME challenges with peptides Melanie Golding, UCB |
| 12:30 | Lunch and Poster viewing |
| Chair: Toby Athersuch, AstraZeneca | |
| 13:30 | Clinical PROTACs: understanding human PK behaviour of protein degraders from different physicochemical space Abhishek Srivastava, AstraZeneca |
| 14:00 | Physicochemical attributes and ADME optimization challenges of oral bifunctional degraders Andy Pike, AstraZeneca |
| 14:30 | An LC-MS/MS method for bioanalysis of a molecular glue, pomalidomide, at sub-ng/mL levels in human plasma Victoria South, Sciex UK |
| 15:00 | Refreshment break and Poster viewing |
| 15:30 | Deep dive into a drug’s subcellular distribution: development of a label-free technology to quantify cytosolic and organelle (un)bound drug concentrations Tom J.J. Schirris, QTM BioSciences B.V |
| 15:45 | Patients with naproxen-induced liver injury display T-cell memory responses towards an oxidative (S)-O-desmethylnaproxen metabolite and not an acyl glucuronide Paul Thomson, University of Liverpool |
| 16:00 | Round table discussion Victoria South, Melanie Golding, Andy Pike, Abhishek Srivastava, Ishwar Singh |
| 16:45 | Closing Remarks and Prize giving Andrew Stachulski, University of Liverpool |
Registration Fees
Registration is now closed!
Early bird Rate (until Friday 3rd May)
Member* £150
Non-member £200
Student** Member* £50
Student** Non-member £75
Standard Rate (from Saturday 4th May)
Member* £200
Non-member £250
Student** Member* £100
Student** Non-member £150
* Member is a full member of the RSC and the DMDG
** Student rates apply to undergraduate, post-graduate and post-doctoral students.
Want to become a member?
To join the RSC and in order to qualify for discounted registration fees, please click here
Sponsorship/Exhibition Opportunities
Registration is now open! Click on the link below to register!
Exhibition Package (£750) includes:
– One stand personnel with access to technical sessions
– A six-foot trestle table and chair(s)
– Electrical and Wi-Fi access
– Your logo on the meetings’ website page
– Your logo and full promotional page in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Any additional stand personnel will have to be booked as delegates
Click here to register as an exhibitor.
Confirmed Exhibitors**FULLY BOOKED
Sponsorship
We are also seeking sponsorship from organisations supporting the low registration fees offered to students. You can support and sponsor this meeting by booking above.
Sponsorship includes
– Your logo on the meetings’ website page
– Your logo in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Your logo included in the communication email to delegates
Confirmed Sponsors
Organising Committee
Toby Athersuch, AstraZeneca UK
Andrew Stachulski, Liverpool University
Xiaoli Meng, Liverpool University
Kevin Beaumont, AstraZeneca UK and DMDG
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
events@hg3.co.uk
